Kwality Pharmaceuticals share price
NSE: KPLFMCGDrug Manufacturers - Specialty & Generic
Kwality Pharmaceuticals at a glance
Kwality Pharmaceuticals (NSE: KPL) closed at ₹3,531.50 on 22 Oct 2026, up 2.93% on the day. With a market capitalisation of ₹3,664 Cr, it ranks 899th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the FMCG sector; its industry is Drug Manufacturers - Specialty & Generic.
Its 52-week range is ₹1,561.00 (21 Apr 2026) to ₹3,949.00 (21 Sep 2026); the last close is 10.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹157 Cr (+35.8% year on year) and net profit ₹25 Cr (+74.8%), on a consolidated basis. Promoters held 54.86% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹3,664 CrRank 899 on NSE
- Price to book
- 11.32×FY26
- EPS (TTM)
- ₹64.90to Q4 FY26
- Debt to equity
- 0.4FY26
- Net profit margin
- 14.6%FY26
- Book value / share
- ₹317.96FY26
- 52-week high
- ₹3,949.0021 Sep 2026
- 52-week low
- ₹1,561.0021 Apr 2026
- RSI (14-day)
- 51.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.93% | +4.6% | −7.1% | +31.3% | — |
Kwality Pharmaceuticals quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹80 Cr | ₹90 Cr | ₹84 Cr | ₹116 Cr | ₹111 Cr | ₹111 Cr | ₹123 Cr | ₹157 Cr |
| Revenue YoY | +18.7% | +29.3% | +8.1% | +25.8% | +39.2% | +23.3% | +46.2% | +35.8% |
| Net profit | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹14 Cr | ₹12 Cr | ₹14 Cr | ₹16 Cr | ₹25 Cr |
| Net profit YoY | +54.6% | +36.0% | +10.9% | +241.5% | +42.8% | +66.9% | +87.8% | +74.8% |
| Net margin | 10.4% | 9.4% | 10.1% | 12.5% | 10.7% | 12.7% | 13.0% | 16.1% |
| EPS | ₹8.04 | ₹8.15 | ₹8.21 | ₹13.95 | ₹11.49 | ₹13.60 | ₹15.42 | ₹24.39 |
Kwality Pharmaceuticals financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹251 Cr | ₹307 Cr | ₹370 Cr | ₹503 Cr |
| Operating profit | ₹46 Cr | ₹47 Cr | ₹62 Cr | ₹98 Cr |
| Net profit | ₹19 Cr | ₹24 Cr | ₹40 Cr | ₹67 Cr |
| EPS (₹) | ₹18.67 | ₹22.93 | ₹38.40 | ₹64.90 |
| Cash from operations | ₹41 Cr | ₹43 Cr | ₹53 Cr | ₹17 Cr |
| Total debt | ₹90 Cr | ₹98 Cr | ₹112 Cr | ₹131 Cr |
| Shareholders' equity | ₹199 Cr | ₹223 Cr | ₹262 Cr | ₹330 Cr |
Kwality Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.83% | 54.83% | 54.83% | 54.83% | 54.87% | 54.86% |
| Foreign institutions | — | — | — | 0.50% | 2.79% | 3.13% |
| Domestic institutions | 0.32% | 0.33% | 0.33% | 0.33% | 0.36% | 0.56% |
| Non-institutions | 44.86% | 44.84% | 44.84% | 44.34% | 41.98% | 41.44% |
Kwality Pharmaceuticals vs peers
The listed FMCG companies nearest to Kwality Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| RENUKAShree Renuka Sugars | ₹19.66 | −1.40% | −33.8% | ₹4,185 Cr | — | — |
| KPLKwality Pharmaceuticals | ₹3,531.50 | +2.93% | — | ₹3,664 Cr | — | — |
| DALMIASUGDalmia Bharat Sugar and Industries | ₹452.25 | −0.40% | +26.6% | ₹3,660 Cr | — | — |
| HERITGFOODHeritage Foods | ₹366.70 | +0.25% | −24.3% | ₹3,403 Cr | 22.6 | — |
| VSTINDVST Industries | ₹200.16 | −0.27% | −18.2% | ₹3,400 Cr | — | — |
| PARAGMILKParag Milk Foods | ₹260.85 | +3.23% | −2.0% | ₹3,277 Cr | 24.7 | — |
| GOPALGopal Snacks | ₹244.40 | +0.47% | −27.3% | ₹3,047 Cr | 41.4 | — |
Ask anything about Kwality Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against KPL's own history. Try: “Why has KPL moved over the last three months?” · “Backtest a 50-day moving-average crossover on KPL over five years” · “Compare KPL with RENUKA on margins and valuation”
Frequently asked questions about Kwality Pharmaceuticals
What is the share price of Kwality Pharmaceuticals today?
Kwality Pharmaceuticals (NSE: KPL) last closed at ₹3,531.50 on 22 Oct 2026. Its 52-week high is ₹3,949.00 and its 52-week low is ₹1,561.00.
What is the market cap of Kwality Pharmaceuticals?
Kwality Pharmaceuticals' market capitalisation is ₹3,664 Cr (₹3,664 Cr) at the 22 Oct 2026 close, ranking 899th among the NSE companies Pivot tracks.
Is Kwality Pharmaceuticals a debt-free company?
No. Kwality Pharmaceuticals' debt-to-equity ratio was 0.4 in FY26, with total debt of ₹131 Cr.
What were Kwality Pharmaceuticals' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Kwality Pharmaceuticals reported revenue of ₹157 Cr, +35.8% year on year, and net profit of ₹25 Cr, +74.8% year on year.
What is the shareholding pattern of Kwality Pharmaceuticals?
As of 30 Jun 2026: promoters 54.86%, foreign institutions 3.13%, domestic institutions 0.56%, non-institutions 41.44%.
Who are Kwality Pharmaceuticals' competitors?
The listed FMCG companies closest to Kwality Pharmaceuticals by market cap are Shree Renuka Sugars, Dalmia Bharat Sugar and Industries, Heritage Foods, VST Industries, Parag Milk Foods and Gopal Snacks.
Is Kwality Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Kwality Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KPL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all FMCG stocks · companies starting with K · all NSE stocks · this page as text